Victoria Katz, MD
Rheumatology · Brooklyn, NYNPI 1508818212
Payments from drug & device makers
Across 764 payments — averaging $38.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$13K
- Amgen$4K
- Mallinckrodt Enterprises LLC$4K
- AstraZeneca$1K
- Johnson & Johnson$1K
- Mallinckrodt Hospital Products Inc.$1K
- plus $5K from 30 others
Across 1 payment — averaging $8357.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$8K
What the payments were for
- Consulting fees$2,92510%
- Speaking & faculty fees$8,80030%
- Travel & lodging$6292%
- Food & beverage$16,48557%
- Education$3101%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 147 | $13,285 |
| Amgen(2 entities) | 194 | $3,827 |
| Mallinckrodt Enterprises LLC | 11 | $3,634 |
| AstraZeneca(2 entities) | 44 | $1,243 |
| Johnson & Johnson(2 entities) | 62 | $1,018 |
| Mallinckrodt Hospital Products Inc. | 58 | $1,016 |
| GSK | 32 | $891 |
| ANI Pharmaceuticals, Inc. | 56 | $784 |
| Lilly USA, LLC | 25 | $650 |
| Novartis | 41 | $564 |
| Aurinia Pharma U.S., Inc. | 15 | $312 |
| Amarin Pharma, Inc. | 7 | $309 |
| E.r. Squibb & Sons, L.L.C. | 11 | $205 |
| Radius Health, Inc. | 7 | $169 |
| Dexcom, Inc. | 1 | $125 |
| Shionogi Inc | 1 | $125 |
| Pfizer | 7 | $121 |
| Regeneron Healthcare Solutions, Inc. | 3 | $85 |
| Boehringer Ingelheim | 3 | $83 |
| Scilex Pharmaceuticals Inc. | 4 | $76 |
| Arbor Pharmaceuticals, Inc. | 4 | $74 |
| Hikma Pharmaceuticals USA | 3 | $63 |
| Bioventus LLC | 3 | $58 |
| UCB, Inc. | 2 | $56 |
| Ferring Pharmaceuticals Inc. | 4 | $53 |
| Sanofi | 3 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Intrinsic Therapeutics | 1 | $46 |
| Genentech USA, Inc. | 2 | $41 |
| Endo Pharmaceuticals Inc. | 2 | $36 |
| Medexus Pharma, Inc. | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 2 | $26 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Bioverativ Therapeutics Inc. | 1 | $22 |
| Cumberland Pharmaceuticals, Inc. | 1 | $21 |
| Shield Therapeutics Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,192 in reported general payments places this provider in the 75th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CortrophinCorticotropin | 77 | $5,028,315 |
| ActharCorticotropin | 20 | $1,380,215 |
| Humira(Cf) PenAdalimumab | 152 | $1,012,864 |
| BenlystaBelimumab | 247 | $867,720 |
| EnbrelEtanercept | 110 | $782,522 |
| Enbrel SureclickEtanercept | 57 | $396,421 |
| Humira(Cf)Adalimumab | 50 | $325,570 |
| Repatha SureclickEvolocumab | 527 | $289,394 |
| SaphneloAnifrolumab-Fnia | 46 | $222,558 |
| Cosentyx (2 Syringes)Secukinumab | 16 | $221,913 |
| RinvoqUpadacitinib | 34 | $205,338 |
| TremfyaGuselkumab | 14 | $189,043 |
| Diclofenac Sodium | 446 | $187,386 |
| ActemraTocilizumab | 41 | $180,418 |
| RayosPrednisone | 47 | $174,179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $1,016 | $1,380,21520 claims |
| AmgenEnbrel, Rayos, Prolia, Evenity (2 Syringes) | $3,827 | $1,151,214269 claims |
| GSKBenlysta | $891 | $867,720247 claims |
| AbbVieHumira(Cf), Rinvoq, Creon, Linzess, Restasis | $13,285 | $722,583282 claims |
| Johnson & JohnsonTremfya, Remicade | $1,018 | $242,98028 claims |
| AstraZenecaSaphnelo | $1,243 | $222,55846 claims |
| NovartisCosentyx (2 Syringes) | $564 | $221,91316 claims |
| Medexus Pharma, Inc.Rasuvo | $34 | $67,421108 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $76 | $56,603148 claims |
| SanofiKevzara | $51 | $51,28012 claims |
| Radius Health, Inc.Tymlos | $169 | $44,46717 claims |
| Lilly USA, LLCMounjaro | $650 | $29,13529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 541 rheumatology providers in New York.
Other rheumatology in Brooklyn
- David GoddardBrooklyn$3.9M
- Amit SaxenaNew York$6.7M
- Cynthia AranowManhasset$5.3M
- Richard FurieNew Hyde Park$4.3M
- Robert SpieraNew York$4.3M
- Laurie GlimcherNew York$3.9M
- Anca AskanaseNew York$3.5M
- Grace WrightNew York$3M
- Jose ScherNew York$2.7M
- Kostas BotsoglouCheektowaga$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.